Global  

CytoDyn to meet with UK regulators to discuss Fast-Track approval for leronlimab, schedules sitdown with FDA

Proactive Investors Wednesday, 2 September 2020
CytoDyn Inc (OTCQB:CYDY) has been granted a meeting with the UK’s Medicines & Healthcare products Regulatory Agency (MHRA) to discuss the its request for fast track approval of leronlimab to treat mild-to-moderate coronavirus (COVID-19) patients, the company announced Wednesday.  At the agency’s suggestion, CytoDyn will submit its current Phase 3 CD12 study for severe-to-critical COVID-19 patients in the UK to the Urgent Public Health (UPH) research scheme to receive possible financial support from the trial sites and the government, if the UPH deems the company’s CD12 trial an urgent health issue. “We are very encouraged by the MHRA’s considering fast track approval of leronlimab and granting us a meeting,” CEO Nader Pourhassan said in a statement. “In this meeting, CytoDyn will present a summary of its BLA for HIV in conjunction with our request for fast track approval for COVID-19 indication. We are also grateful to the MHRA for advising us about potential financial support from the sites and UK government for our CD12 study currently in process.” READ: CytoDyn forms Scientific Advisory Board, including leading HIV, NASH, Oncology, and Rheumatological clinical experts and researchers Additionally, CytoDyn was informed by the US Food and Drug Administration (FDA) that the agency has scheduled a Type A meeting for September 8. A Type A meeting is immediately necessary for a stalled drug development to proceed, according to agency documents. The company received answers from the FDA to questions regarding its Biologics License Application (BLA) for leronlimab as a combination therapy for highly treatment-experienced HIV patients. The FDA clarified the items it needed primarily related to dosage levels, the company said. “We also look forward to meeting with the FDA to help expedite the resubmission of our BLA, as well as learning whether we receive Emergency Use Approval for leronlimab for COVID-19 or, alternatively, are required to proceed with a Phase 3 trial,” Pourhassan said. “Regardless, we are working diligently to ensure the availability of leronlimab worldwide to provide a potential benefit for patients infected with this terrible disease.” Contact Andrew Kessel at [email protected] Follow him on Twitter @andrew_kessel
2
shares
ShareTweetSavePostSend
 

You Might Like


Related videos from verified sources

LabCorp Covid-19 Test Gets Fast-Track FDA Emergency Approval [Video]

LabCorp Covid-19 Test Gets Fast-Track FDA Emergency Approval

LabCorp has received emergency authorization approval from the Food and Drug Administration to roll out a new rapid Covid-19 test.

Credit: The Street     Duration: 02:27Published
FDA, EU diverge on AstraZeneca COVID-19 vaccine [Video]

FDA, EU diverge on AstraZeneca COVID-19 vaccine

The Food and Drug Administration widened its probe into a serious illness linked to halted clinical trials for AstraZeneca's potential COVID-19 vaccine, sources told Reuters, while in Europe the..

Credit: Reuters Studio     Duration: 01:42Published

Related news from verified sources

CytoDyn selected to make oral presentation at the “Special isirv-AVG Virtual Conference on Therapeutics for COVID-19”

CytoDyn Inc (OTCQB:CYDY), which is developing its flagship drug leronlimab (PRO 140) to battle multiple diseases, said Wednesday that its Phase 2 study of...
Proactive Investors


Tweets about this